Atezolizumab: Phase II started

Immune Design Corp. (NASDAQ:IMDZ, Seattle, Wash.) began an open-label, U.S. Phase II trial to compare CMB305 with atezolizumab vs. atezolizumab alone in up to 80 patients. Immune Design is developin...